Pharmacokinetics of cefamandole in patients undergoing hemodialysis. 1979

J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio

The pharmacokinetics of Cefamandole was studied in 17 patients with terminal renal impairment, 10 of which were undergoing sessions of hemodialysis while 7 were in the period between dialysis sessions. An open two-compartment kinetic model was used to describe the bi-phasic decrease of the plasma concentrations of Cefamandole thus establishing the amounts of the antibiotic in the peripheral and central compartments together with the amount eliminated. All patients received an i.v. bolus injections of 15 mg/kg body weight. During the hemodialysis sessions, the pharmacokinetic parameters of Cefamandole were the following: alpha = 5.006 hr-1 beta = 0.182 hr-1 K12 = 2.598 hr-1 K21 = 2.147 hr-1 K13 = 0.441 hr-1 Vc = 5.700 l Vp = 6.190 l Vdss = 11.94 l It may be seen that there is a decrease in the overall elimination constant compared with that obtained during the periods between the dialysis sessions. A dosage regimen of multiple doses is established as a function of the pharmacokinetic parameters of the antibiotic for patients with terminal renal impairment undergoing periodic sessions of hemodialysis.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002435 Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate. Cephamandole,Compound 83405
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
September 1976, Antimicrobial agents and chemotherapy,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
October 1976, Antimicrobial agents and chemotherapy,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
November 1979, Clinical pharmacology and therapeutics,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
January 1982, Methods and findings in experimental and clinical pharmacology,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
December 1991, The Japanese journal of antibiotics,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
August 1979, International journal of clinical pharmacology and biopharmacy,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
July 1991, Journal of clinical pharmacology,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
January 1983, Nephron,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
October 1986, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and J M Tabernero, and F Rubio
April 2017, Hemodialysis international. International Symposium on Home Hemodialysis,
Copied contents to your clipboard!